Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland.
Department of Endocrinology, Diabetes and Isotope Therapy, Students research association, Wroclaw Medical University, Wroclaw, Poland.
Front Endocrinol (Lausanne). 2022 Jun 9;13:867965. doi: 10.3389/fendo.2022.867965. eCollection 2022.
Ectopic acromegaly is a rare condition caused most frequently by growth hormone releasing hormone (GHRH) secretion from neuroendocrine tumors. The diagnosis is often difficult to establish as its main symptoms do not differ from those of acromegaly of pituitary origin.
To determine most common clinical features and diagnostic challenges in ectopic acromegaly.
A search for ectopic acromegaly cases available in literature was performed using PubMed, Cochrane, and MEDline database. In this article, 127 cases of ectopic acromegaly described after GHRH isolation in 1982 are comprehensively reviewed, along with a summary of current state of knowledge on its clinical features, diagnostic methods, and treatment modalities. The most important data were compiled and compared in the tables.
Neuroendocrine tumors were confirmed in 119 out of 121 patients with histopathological evaluation, mostly of lung and pancreatic origin. Clinical manifestation comprise symptoms associated with pituitary hyperplasia, such as headache or visual field disturbances, as well as typical signs of acromegaly. Other endocrinopathies may also be present depending on the tumor type. Definitive diagnosis of ectopic acromegaly requires confirmation of GHRH secretion from a tumor using either histopathological methods or GHRH plasma concentration assessment. Hormonal evaluation was available for 84 patients (66%) and histopathological confirmation for 99 cases (78%). Complete tumor resection was the main treatment method for most patients as it is a treatment of choice due to its highest effectiveness. When not feasible, somatostatin receptor ligands (SRL) therapy is the preferred treatment option. Prognosis is relatively favorable for neuroendocrine GHRH-secreting tumors with high survival rate.
Although ectopic acromegaly remains a rare disease, one should be aware of it as a possible differential diagnosis in patients presenting with additional symptoms or those not responding to classic treatment of acromegaly.
异位性肢端肥大症是一种罕见的疾病,主要由生长激素释放激素(GHRH)分泌的神经内分泌肿瘤引起。由于其主要症状与垂体起源的肢端肥大症无明显差异,因此诊断通常较为困难。
确定异位性肢端肥大症的常见临床特征和诊断挑战。
通过 PubMed、Cochrane 和 MEDline 数据库对 1982 年 GHRH 分离后文献中报道的异位性肢端肥大症病例进行搜索。本文全面回顾了 121 例经组织病理学证实的异位性肢端肥大症病例,同时总结了其临床特征、诊断方法和治疗方式的最新知识。最重要的数据以表格形式进行了编译和比较。
119 例患者经组织病理学评估证实存在神经内分泌肿瘤,主要来源于肺部和胰腺。临床表现包括与垂体增生相关的症状,如头痛或视野障碍,以及肢端肥大症的典型体征。根据肿瘤类型,还可能存在其他内分泌疾病。异位性肢端肥大症的明确诊断需要通过组织病理学方法或 GHRH 血浆浓度评估确认肿瘤分泌 GHRH。对 84 例患者(66%)进行了激素评估,对 99 例患者(78%)进行了组织病理学证实。大多数患者采用肿瘤完全切除术作为主要治疗方法,因为这是最有效的治疗方法。当无法进行手术时,生长抑素受体配体(SRL)治疗是首选的治疗方案。神经内分泌 GHRH 分泌肿瘤的预后相对较好,生存率较高。
尽管异位性肢端肥大症仍然是一种罕见疾病,但对于出现额外症状或对经典肢端肥大症治疗无反应的患者,应将其作为可能的鉴别诊断。